JNJ vs MRK
Johnson & Johnson and Merck & Co. Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
Most recent reported year
| Metric | JNJ | MRK |
|---|---|---|
| Revenue | $94.2B | $65.0B |
| Net income | $26.8B | $18.3B |
| Gross margin | 67.9% | 74.8% |
| Net margin | 28.5% | 28.1% |
| Return on equity | 35.0% | 36.9% |
| Diluted EPS | $11.03 | $7.28 |
| Dividend / share | $5.14 | $3.28 |
| Payout ratio | · | 44.8% |
| Free cash flow | $19.7B | $12.4B |
| Equity | · | $52.6B |
| Net debt / equity | 0.27× | 0.66× |
| Current ratio | 1.03× | 1.54× |
| Revenue CAGR 5y | 2.7% | 9.4% |
| Profit CAGR 5y | 12.7% | 20.9% |
JNJ bills 1.4× the revenue of MRK, and keeps more of each dollar of revenue as profit (28.5% against 28.1%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner. "·" marks a figure not available in our data.
10 years side by side
| Fiscal year | JNJ | MRK |
|---|---|---|
| FY2025 | $94.2B | $65.0B |
| FY2024 | $88.8B | $64.2B |
| FY2023 | $85.2B | $60.1B |
| FY2022 | $80.0B | $59.3B |
| FY2021 | $78.7B | $48.7B |
| FY2020 | $82.6B | $41.5B |
| FY2019 | $82.1B | $39.1B |
| FY2018 | $81.6B | $42.3B |
| FY2017 | $76.5B | $40.1B |
| FY2016 | $71.9B | $39.8B |
Bottom line
| Fiscal year | JNJ | MRK |
|---|---|---|
| FY2025 | $26.8B | $18.3B |
| FY2024 | $14.1B | $17.1B |
| FY2023 | $35.2B | $365.0M |
| FY2022 | $17.9B | $14.5B |
| FY2021 | $20.9B | $13.0B |
| FY2020 | $14.7B | $7.1B |
| FY2019 | $15.1B | $9.8B |
| FY2018 | $15.3B | $6.2B |
| FY2017 | $1.3B | $2.4B |
| FY2016 | $16.5B | $3.9B |
19 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +$29,182,000,000 | JNJ |
| FY2024 | +$24,653,000,000 | JNJ |
| FY2023 | +$25,044,000,000 | JNJ |
| FY2022 | +$20,707,000,000 | JNJ |
| FY2021 | +$30,036,000,000 | JNJ |
| FY2020 | +$41,066,000,000 | JNJ |
| FY2019 | +$42,938,000,000 | JNJ |
| FY2018 | +$39,287,000,000 | JNJ |
| FY2017 | +$36,328,000,000 | JNJ |
| FY2016 | +$32,083,000,000 | JNJ |
| FY2015 | +$30,576,000,000 | JNJ |
| FY2014 | +$32,094,000,000 | JNJ |
| FY2013 | +$27,279,000,000 | JNJ |
| FY2012 | +$19,957,000,000 | JNJ |
| FY2011 | +$16,983,000,000 | JNJ |
| FY2010 | +$15,600,000,000 | JNJ |
| FY2009 | +$34,469,000,000 | JNJ |
| FY2008 | +$39,897,000,000 | JNJ |
| FY2007 | +$36,897,300,000 | JNJ |
JNJ has reported the higher revenue in every one of these 19 fiscal years. The gap has narrowed since the earliest year compared.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
19 fiscal years
| Fiscal year | Difference | Ahead |
|---|---|---|
| FY2025 | +0.4 pp | JNJ |
| FY2024 | −10.9 pp | MRK |
| FY2023 | +40.7 pp | JNJ |
| FY2022 | −2.1 pp | MRK |
| FY2021 | −0.3 pp | MRK |
| FY2020 | +0.8 pp | JNJ |
| FY2019 | −6.6 pp | MRK |
| FY2018 | +4.1 pp | JNJ |
| FY2017 | −4.3 pp | MRK |
| FY2016 | +13.1 pp | JNJ |
| FY2015 | +10.7 pp | JNJ |
| FY2014 | −6.3 pp | MRK |
| FY2013 | +9.1 pp | JNJ |
| FY2012 | +2.3 pp | JNJ |
| FY2011 | +1.6 pp | JNJ |
| FY2010 | +19.5 pp | JNJ |
| FY2009 | −27.7 pp | MRK |
| FY2008 | −12.9 pp | MRK |
| FY2007 | +3.3 pp | JNJ |
The higher net margin has changed hands between JNJ and MRK over this period.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRK's net margin has been more volatile than JNJ's over the 19 comparable fiscal years — 11.4 percentage points of standard deviation against 7.3.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in net margin changed hands between JNJ and MRK over these 19 fiscal years — JNJ led in 11 and MRK in 8.
19 of 19 comparable fiscal years — a year missing data on either side is not counted.
Standard deviation, each side
MRK's return on equity has been more volatile than JNJ's over the 18 comparable fiscal years — 14.4 percentage points of standard deviation against 8.8.
18 of 19 comparable fiscal years — a year missing data on either side is not counted.
Year by year
The lead in return on equity changed hands between JNJ and MRK over these 18 fiscal years — JNJ led in 8 and MRK in 10.
18 of 19 comparable fiscal years — a year missing data on either side is not counted.